Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine liposomal suspension - FUJIFILM Corporation

Next Previous
Drug Profile

Gemcitabine liposomal suspension - FUJIFILM Corporation

Alternative Names: F832; FF-10832

Latest Information Update: 10 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FUJIFILM Corporation
  • Developer FUJIFILM Corporation; Merck & Co
  • Class Amines; Antineoplastics; Deoxyribonucleosides; Fluorinated hydrocarbons; Ketones; Pyrimidine nucleosides; Pyrimidines; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 31 May 2024 Efficacy, adverse event, pharmacokinetics and immunogenicity data from a phase II trial in Solid tumour presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 03 Jun 2022 Safety and pharmacokinetics data from a phase I trial in Solid tumours presented at the 58th annual meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 01 Jun 2022 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05318573)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top